Inhibitory Effect of P22077 on Airway Inflammation in Rats with COPD and Its Mechanism
DOI: https://doi.org/10.2147/copd.s451244
2024-03-20
International Journal of COPD
Abstract:Di Zeng, 1, &ast Wenbo Zhang, 2, &ast Xiaoju Chen, 3 Guochun Ou, 4 Yuewei Huang, 2 Chengxiu Yu 2 1 Department of General Practice, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China; 3 Clinical Medical College, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, People's Republic of China; 4 Department of Respiratory and Critical Care Medicine, Suining Central Hospital, Suining, Sichuan, 629000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoju Chen, Clinical Medical College, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081, People's Republic of China, Email Purpose: Here, we studied the pharmacological effect of P22077 on airway inflammation induced by lipopolysaccharide and cigarette smoke and explored the therapeutic mechanism of P22077 in COPD model RAT. Patients and Methods: The COPD model was established by lipopolysaccharide combined with fumigation; animals were treated with vehicle or P22077. Serum, bronchoalveolar lavage fluid (BALF), and lung tissues were collected for analysis. Results: Our results showed that P22077 treatment significantly improved the airway inflammation of COPD model RAT and reduced the recruitment of leukocytes in BALF, and hypersecretion of interleukin-18 (IL-18), interleukin-1β (IL-1β) in BALF and serum. H&E staining showed that P22077 treatment could effectively reduce emphysema, immune cell infiltration and airway wall destruction. PAS staining showed that The proliferation of cup cells in the airway wall and the number of bronchial cup cells were significantly reduced in rats treated with P22077. In addition, we found that P22077 treatment suppressed the generation of the NLRP3/ASC/Caspase 1 inflammasome complex to inhibit the inflammatory response caused by IL-1β and IL-18. Conclusion: Conclusion: P22077 inhibits expression of NLRP3 pathway-related inflammatory factors and proteins and reduces the airway inflammatory response and inflammatory cell aggregation in COPD rats. The underlying mechanism may be related to the down-regulation of NLRP3 inflammatory vesicle signaling pathway expression. Keywords: COPD, ubiquitinase inhibitors, P22077, airway inflammation, NLRP3 Chronic obstructive pulmonary disease (COPD) is one of the most common diseases of the respiratory system. COPD is a chronic inflammatory disease of the airways, lung parenchyma, and pulmonary vasculature caused by chronic infiltration of inflammatory cells from long-term exposure to harmful gases, dust, and other particles and complex interactions with the host's factors. The incidence and disease burden of COPD will increase in the coming decades because of ongoing exposure to risk factors caused by environmental and social health issues and an aging population worldwide. 1 By 2030, COPD will be the fourth leading cause of death worldwide and the seventh leading cause of the global burden of disease. 2 While studies on COPD are increasing, the pathogenesis of COPD is very complex and still not fully understood. Inflammation has been identified as one of the main causes of COPD onset and recurrent acute exacerbations. Even if the triggers of onset are removed, inflammation caused by an excessive or inadequate immune response will still persist and lead to chronic inflammation 3. Repeated irritation of the respiratory tract from various causes enriches inflammatory cells in the airways and lung tissue, stimulating the release of inflammatory mediators to trigger an inflammatory response, which becomes more pronounced and worsens with the development of disease. Inflammatory vesicles are closely related to the inflammatory response. 4 Currently, there are five types of inflammasome, among which the NLRP3 inflammasome is the one with the most attention and the most in-depth research. It consists of Nod-like receptor protein 3 as the receptor, ASC as the adaptor, and caspase-1 as the effector. 5 The recognition of danger signals by macrophages can lead to the aggregation of NLPR3 molecular complexes and the subsequent maturation of inflammatory vesicles and activation of caspase 1, leading to the release of cytokines such as IL-1β and IL-18 to participate in the inflammatory response. The roles of NLPR3 molecular complexes and the IL-1β and IL-18 cytokines in inflammatory diseases are gaining attention. The activation o -Abstract Truncated-
respiratory system